Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pacific Edge Limited ( (PFGTF) ) has provided an announcement.
Pacific Edge Limited reported resilient demand for its Cxbladder tests despite losing Medicare coverage in April 2025 and transitioning US customers from Detect to Triage. The company is engaging with Medicare Administrative Contractor Novitas to reconsider coverage based on new evidence, including a randomized control study and updated guidelines. While US test volumes decreased due to the transition, the Cxbladder Triage test saw increased adoption, now representing 77% of US throughput. Despite disruptions, key US customer volumes remained stable, and Asia Pacific volumes grew by 8.8%. The company is also preparing for an annual meeting and a capital raising initiative.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company headquartered in Dunedin, New Zealand. It specializes in the development and commercialization of bladder cancer diagnostic and prognostic tests, particularly through its Cxbladder suite of non-invasive genomic urine tests. These tests are designed for patients with microhematuria and those under surveillance for recurrent disease, aiming to improve patient experience and optimize clinical workflow. The company operates CLIA certified laboratories in New Zealand and the USA, and its products are available in the US, Australasia, Israel, and various markets in Asia and South America.
For a thorough assessment of PFGTF stock, go to TipRanks’ Stock Analysis page.